Phase 1 dose‐escalation study of single‐agent veliparib in Japanese patients with advanced solid tumors

Veliparib (ABT‐888) is a potent, orally bioavailable poly(ADP‐ribose) polymerase‐1 and ‐2 inhibitor. This phase 1 study evaluated the tolerability, pharmacokinetic profile, safety, and preliminary antitumor activity of single‐agent veliparib in Japanese patients with advanced solid tumors. Eligible...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Sci
Main Authors: Nishikawa, Tadaaki, Matsumoto, Koji, Tamura, Kenji, Yoshida, Hiroyuki, Imai, Yuichi, Miyasaka, Aki, Onoe, Takuma, Yamaguchi, Satoshi, Shimizu, Chikako, Yonemori, Kan, Shimoi, Tatsunori, Yunokawa, Mayu, Xiong, Hao, Nuthalapati, Silpa, Hashiba, Hideyuki, Kiriyama, Tsukasa, Leahy, Terri, Komarnitsky, Philip, Fujiwara, Keiichi
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2017
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5581522/
https://ncbi.nlm.nih.gov/pubmed/28665051
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.13307
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados